Centrosome-associated protein 350 (2297-2305)

Centrosome-associated protein 350 (2297-2305) is a synthetic peptide fragment derived from the C-terminal region of the large centrosomal protein CEP350, a key player in microtubule organization and centrosome function. This peptide corresponds to amino acid residues 2297 to 2305 of the human CEP350 sequence, making it a highly specific molecular tool for researchers investigating the structural and regulatory roles of centrosomal proteins. Its defined sequence and origin from a functionally significant region of CEP350 enable targeted studies into protein-protein interactions, post-translational modifications, and the broader dynamics of centrosome-associated complexes within the cell.

Antibody generation: As a defined epitope, the 2297-2305 peptide is frequently utilized as an immunogen for the production of polyclonal and monoclonal antibodies against CEP350. These antibodies are invaluable for probing endogenous CEP350 expression, localization, and dynamics in cell biology experiments, including immunofluorescence, immunoprecipitation, and western blotting. The specificity afforded by this peptide segment ensures minimal cross-reactivity, supporting high-fidelity detection and quantification of the target protein in complex biological samples.

Protein interaction studies: The peptide serves as a precise molecular probe for mapping interaction sites within the CEP350 protein or between CEP350 and its binding partners. By synthesizing and immobilizing this sequence, researchers can perform in vitro binding assays, such as peptide pull-downs or surface plasmon resonance, to identify and characterize proteins that recognize the 2297-2305 region. These studies provide mechanistic insight into the assembly of centrosomal complexes and the regulation of microtubule anchoring.

Phosphorylation and post-translational modification analysis: The centrosome-associated protein 350 (2297-2305) peptide is suitable for examining site-specific phosphorylation or other post-translational modifications that may occur within this region of CEP350. Synthetic peptides enable the generation of modification-specific antibodies or serve as substrates in kinase assays, facilitating the investigation of regulatory pathways that control centrosome function and cell cycle progression.

Peptide competition assays: In functional studies, the 2297-2305 peptide can be used as a competitive inhibitor to disrupt endogenous protein-protein interactions involving CEP350. By introducing the peptide into cell lysates or in vitro systems, researchers can assess the biological consequences of blocking this interaction site, thereby elucidating the functional significance of the corresponding domain within the full-length protein.

Mass spectrometry calibration and method development: The well-defined sequence and physicochemical properties of the centrosome-associated protein 350 (2297-2305) peptide make it a valuable standard for optimizing mass spectrometry-based proteomic workflows. It can be employed to calibrate instrumentation, validate peptide identification algorithms, or serve as a reference in targeted quantification assays, enhancing the reliability and reproducibility of protein analysis in centrosome research.

1. Adipose tissue is a key organ for the beneficial effects of GLP-2 metabolic function

2. C-Peptide replacement therapy and sensory nerve function in type 1 diabetic neuropathy

3. TMEM16F and dynamins control expansive plasma membrane reservoirs

4. Novel Peptide-Based PD1 Immunomodulators Demonstrate Efficacy in Infectious Disease Vaccines and Therapeutics

5. Low bone turnover and low BMD in Down syndrome: effect of intermittent PTH treatment